Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Avoiding Medicare: Lilly, Icos and Limiting Part D Exposure

This article was originally published in RPM Report

Executive Summary

Lilly's acquisition of Icos is a big bet on the future of private pay medicines. Lilly is paying $2.1 billion for sole rights to Cialis, in part because the company is happy to have a brand that operates outside of the influence of managed care gatekeepers in the US.

You may also be interested in...



Can You Hear That Whistle Blow? Sales Force Reductions Come with Risks

Pfizer's big sales force cuts mark the beginning of a disarmament in sales infrastructure across the pharmaceutical industry. That means a lot of sales reps will be out of work-and looking for payback.

Can You Hear That Whistle Blow? Sales Force Reductions Come with Risks

Pfizer's big sales force cuts mark the beginning of a disarmament in sales infrastructure across the pharmaceutical industry. That means a lot of sales reps will be out of work-and looking for payback.

A Cold Shower For Viagra: How Congress Can Chill A Market

Pfizer, Lilly and the other marketers of drugs for erectile dysfunction are kicked out of Medicare and Medicaid. Viagra and the other brands may be the first victims of the backlash against DTC advertising. They are also a case study in how Congress can--and well--make mischief under the Medicare program.

Topics

Related Companies

UsernamePublicRestriction

Register

PS079971

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel